KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) EBIT (2016 - 2025)

BeOne Medicines (ONC) has disclosed EBIT for 11 consecutive years, with $185.0 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIT rose 332.97% to $185.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $447.1 million, a 178.69% increase, with the full-year FY2025 number at $447.1 million, up 178.69% from a year prior.
  • EBIT was $185.0 million for Q4 2025 at BeOne Medicines, up from $163.1 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $190.6 million in Q4 2021 to a low of -$474.8 million in Q2 2021.
  • A 5-year average of -$189.7 million and a median of -$197.7 million in 2023 define the central range for EBIT.
  • Peak YoY movement for EBIT: crashed 731.76% in 2022, then soared 332.97% in 2025.
  • BeOne Medicines' EBIT stood at $190.6 million in 2021, then crashed by 345.92% to -$468.6 million in 2022, then increased by 18.1% to -$383.8 million in 2023, then skyrocketed by 79.31% to -$79.4 million in 2024, then skyrocketed by 332.97% to $185.0 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's EBIT are $185.0 million (Q4 2025), $163.1 million (Q3 2025), and $87.9 million (Q2 2025).